Chronic myeloid leukaemia at the Kenyatta National Hospital, Nairobi

East African Medical Journal

Volumn 79, Issue 11, 2002, Pages 593-597

  Othieno Abinya, N A ^a   Nyabola, L O ^a   Kiarie, G W ^a   Ndege, R ^a   Maina, J M D ^b  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b KENYATTA NATIONAL HOSPITAL   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; HYDROXYUREA; ALKYLATING AGENT; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; FEMALE; FOLLOW UP; HOSPITAL; HUMAN; KENYA; MAJOR CLINICAL STUDY; MALE; SCHOOL CHILD; TREATMENT OUTCOME; AGE DISTRIBUTION; BLOOD; CHILD; CLASSIFICATION; HOSPITALIZATION; LEUKOCYTE COUNT; MIDDLE AGED; RETROSPECTIVE STUDY; SPLENOMEGALY; SURVIVAL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CHILD; FEMALE; HUMANS; HYDROXYUREA; KENYA; LEUKEMIA, MYELOID, CHRONIC; LEUKOCYTE COUNT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPLENOMEGALY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036879363     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: 10.4314/eamj.v79i11.8805     Document Type: Article

References (18)

1. Nowell, P.C. and Hungerford, D.A. A minute chromosome in human chronic granulocytic leukaemia. Science. 1960; 132: 1497-1501.
2. Rowley, J.D. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature. 1973, 253: 290-293.
3. Davis, R.L., Konopka, J.B. and Witte, O.N. Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties. Mol. Cell. Biol. 1985; 5: 204.
4. + CML - CP). Proc. Am. Soc. Clin. Oncol. 2002; 21 (Abstr 1043): 261a.
5. Cortes, J.E., Talpaz, M., Giles, F.J. et al. High-dose imatinib mesylate (ST157 1, Gleevec) in patients with chronic myeloid leukaemia (CML) resistant or intolerant to interferon-alpha (IFN). Proc. Am. Soc. Clin. Oncol. 2002; 21(Abstr 1044): 262a.
6. Hasford, J., Pfirrmann, M., Hehlmann, R. et al. A new prognostic score for survival of patients with chronic myeloid leukaemia treated with interferon-alpha: Writing Committee for collaborative CML Prognostic Factors Project Group. J. Natl. Cancer Inst. 1998; 90: 850.
7. Kantarjian, H.M., Keating, M.J., Smith, T.L. et al. Proposal for a simple synthesis prognostic staging system in chronic myelogneous leukaemia. Am. J. Med. 1990, 88: 1-8.
8. Sokal, J.E., Cox, E.B., Baccarani, M. et al. Prognostic discrimination in "good risk" chronic granulocytic leukaemia. Blood. 1984; 63: 789-799.
9. Hehlmann, R., Ansari, H., Hasford, J. et al. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score: German chronic myeloid leukaemia (CML) Study Group. Brit. J. Haematol. 1997; 97: 76.
10. Hasford, J., Ansari, H., Pffirmann, M. et al. Analysis and validation of prognostic factors for CML. German CML Study Group. Bone marrow Transplant. 1996; 17:S49-S54.
11. Thiele, J., Kvasnicka, H.M., Titius, B.R. et al. Histologic features of prognostic significance in CML: An immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow. Ann. Hematol. 1993; 66: 291-302.
12. 1+ chronic myelogenous leukaemia: A multicenter trial. J. Clin. Oncol. 2001; 19: 2994-3009.
13. Hehlmann, R., Heimpel, H., Hasford, J., et al. Randomized comparison of interferon-alpha with busulphan and hydroxyurea in chronic myelogenous leukaemia. Blood. 1994; 84: 4064-4077.
14. Goldman, J., Szydlo, R., Horowitz, M. et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukaemia in chronic phase. Blood. 1993, 82: 2235-2238.
15. Allan, N.C., Richards, S.M., Shepherd, P.C.A. UK Medical Research Council randomized multicentre trial of interferon-alpha for chronic myeloid leukaemia; Improved survival irrespective of cytogenetic response. Lancet. 1995; 345: 1392-1397.
16. The Italian cooperative study group of chronic myeloid leukaemia. Interferon-alpha 2a as compared with conventional chemotherapy for treatment of chronic myeloid leukaemia. N. Engl. J. Med. 1994, 330: 820-825.
17. Ma, D.D.F. and Arthur, C.K. Treatment of chronic myelogenous leukaemia (CML) using alpha-interferon (IFN), and low dose cytosine arabinoside (ara-C). Blood. 1989; 74: 363A.
18. Kantarjian, H., Keating, M., McCredie, K. et al. Treatment of advanced stages of Philadelphia chromosome (Ph) - positive chronic myelogenous leukaemia (CML) with alpha-interferon (IFN- A) and low dose cytosine arabinoside (ara-C). Blood. 1989; 7: 235A.